Novavax, Inc.

Last price update: 18 Jun 24 23:00 GMT

Price:
$13.79
Open:
$13.99
Previous close:
$14.05
Day's range:
$13.06 - $14.48
Year's range:
$3.53 - $23.86
Net Income per Share:
-3.05
Price-to-Earnings ratio:
-4.52
52-week Price Range:
$10.06
Volume:
$14,384,215.00
Average volume:
$14,913,920.00

Company profile for Novavax, Inc.

Novavax, Inc. logo

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company’s vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Stock exchanges:
NASDAQ
Sector:
Healthcare
Industries:
Biotechnology
Ticker:
NVAX
CIK:
1000694
ISIN:
US6700024010
Website:
https://www.novavax.com
Phone:
240 268 2000
Origin:
United States
Employees:
1,541